sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 48 NHL / NHLFIT


News
1. Overview
Study details
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms


return to top

News


No news


1. Overview



Summary

Efficacy and safety of subsequent treatment with 90Y-ibritumomab tiuxetan versus no further treatment in patients with stage III or IV follicular non-Hodgkin?s lymphoma having achieved partial or complete remission after first line chemotherapy. A prospective, multicenter, randomized phase III clinical trial


Status

closed


Members

The HOVON 48 NHL study is executed by Schering AG. For more information please contact:
Dr. M.H.J. van Oers AMC Amsterdam
(studiecoordinator for the Netherlands)
Prof. Dr. A. Hagenbeek UMCU Utrecht
(studiecoordinator)



Study details



Type of study

Prospective randomized Phase III study


Date of activation

09-Aug-2001


Date closed

20-Jan-2005


2. Patient eligibility criteria



3. Registration (& randomization) of patients



Registration

Central registration at the HOVON Data Center:
Erasmus MC Cancer Institute, Clinical Trial Center (Hs-423)
P.O. Box 2040
NL-3000 CA Rotterdam
Phone number.: +31.10.7041560 (working days 9.00-17.00)
Fax number.....: +31.10.7041028
TOP address...: http://www.hdc.hovon.nl/top


4. Participating parties



Coordinating investigator(s)

Dr. M.H.J. van Oers AMC Amsterdam
(studiecoordinator for the Netherlands)
Prof. Dr. A. Hagenbeek UMCU Utrecht
(studiecoordinator)


Other functions

Please contact monitors at hdcmonitorteam@erasmusmc.nl


5. Participating sites



6. Instruction videos



7. Download documentation / forms


 Protocol



return to top